Crinetics Pharmaceuticals
CRNX
122 hedge funds and large institutions have $948M invested in Crinetics Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 45 increasing their positions, 28 reducing their positions, and 13 closing their positions.
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
61% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 28
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
10% more funds holding
Funds holding: 111 → 122 (+11)
7% more capital invested
Capital invested by funds: $885M → $948M (+$63.3M)
1.4% more ownership
Funds ownership: 94.65% → 96.05% (+1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.5M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$10.6M |
| 3 |
BNP Paribas Asset Management
Paris,
France
|
+$9.29M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$7.74M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$3.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$21M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.23M |
| 3 |
Millennium Management
New York
|
-$3.83M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$3.83M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.15M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
AQR Capital Management
Greenwich,
Connecticut
| – | -$189K | -10,138 | Closed |
|
|
DCM
127
Dupont Capital Management
Wilmington,
Delaware
| – | -$161K | -8,629 | Closed |
|
128
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$22K | -1,192 | Closed |
|
129
Simplex Trading
Chicago,
Illinois
| – | -$11.3K | -552 | Closed |
|
|
BFEC
130
Benjamin F. Edwards & Company
St. Louis,
Missouri
| – | -$4K | -200 | Closed |
|
|
SOW
131
State of Wyoming
Cheyenne,
Wyoming
| – | -$1K | -70 | Closed |
|
|
C
132
Covestor
London,
United Kingdom
| – | -$20 | -1 | -11% |
|
|
PA
133
Parallel Advisors
San Francisco,
California
| – | +$122 | +6 | New |
|
|
AF
134
Allworth Financial
Folsom,
California
| – | +$204 | +10 | New |
|
|
BWL
135
Bogart Wealth LLC
Mclean,
Virginia
| – | +$510 | +25 | New |
|
CRNX Hedge Fund Activity: Q3 2022 in Review
122 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q3 2022, worth a combined $948M — up 7.2% from $885M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CRNX positions and 13 closed out — a net gain of 11 holders — while 45 added to existing stakes and 28 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $16.5M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $21M sold.
- 122 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q3 2022, up from 111 in Q2 2022.
- Funds reported $948M of Crinetics Pharmaceuticals stock for Q3 2022, up 7.2% quarter-over-quarter.
- 24 funds opened new Crinetics Pharmaceuticals positions in Q3 2022 and 13 closed out, a net change of +11 holders.
- The largest Crinetics Pharmaceuticals buyer in Q3 2022 was Wellington Management Group, an estimated $16.5M added.
- The largest Crinetics Pharmaceuticals seller in Q3 2022 was Suvretta Capital Management, an estimated $21M sold.
Based on aggregated 13F filings for Q3 2022.